 "Wockhardt")
Drug firm Wockhardt posted a net profit of Rs 16 crore in the quarter ended June, 80 per cent down from the corresponding quarter of FY16, mainly on account of dip in sales and increased expenditure. In the first quarter (Q1) of FY16, the company had reported a profit of Rs 97 crore.
The India business of the company grew a marginal 10 per cent, despite launching 11 new products in the market.
Wockhardt’s consolidated revenues for Q1FY17 is at Rs 1,071 crore.
Around 62 per cent of its revenue for the quarter ended June came from international operations. Of the international revenue, the US contributed 18 per cent.
Wockhardt’s UK business grew 26 per cent, compared to Q1FY16. The company made three new fillings and received one approval for the UK market.
The company filed 97 patents in the quarter ended June, bringing it to a total of 2,676 cumulative filings.
The India business of the company grew a marginal 10 per cent, despite launching 11 new products in the market.
Wockhardt’s consolidated revenues for Q1FY17 is at Rs 1,071 crore.
Around 62 per cent of its revenue for the quarter ended June came from international operations. Of the international revenue, the US contributed 18 per cent.
Wockhardt’s UK business grew 26 per cent, compared to Q1FY16. The company made three new fillings and received one approval for the UK market.
The company filed 97 patents in the quarter ended June, bringing it to a total of 2,676 cumulative filings.
